This week's valuation screen surfaced five companies where modeled cash flows and market pricing are sending sharply different signals. Using the FMP DCF Valuation API, this article examines the gaps across Bristol-Myers Squibb, ResMed, Accenture, AIG, and PayPal, then explains how the same API can support a repeatable valuation-monitoring workflow.
Key Takeaways
- The FMP DCF Valuation API identified substantial gaps between modeled value and market price across Bristol-Myers Squibb, ResMed, Accenture, AIG, and PayPal.
- The common signal is not sector-specific; each company reflects a different debate around cash-flow durability, operating risk, and market confidence.
- The widest valuation spreads require company-specific validation, particularly for insurers, pharmaceutical companies, and businesses undergoing structural change.
- Combining DCF outputs with income statements, cash-flow data, balance sheets, analyst estimates, and price targets produces a more reliable research framework than using a single valuation measure.
Five Companies Defining This Week's Valuation Screen
Bristol-Myers Squibb Company (BMY)
DCF Value: $252.01 — Market Price: $62.09 → Upside Potential: 305.9%
Bristol-Myers Squibb shows one of the widest gaps in this week's screen. The FMP DCF estimate of $252.01 stands more than four times above the stated market price of $62.09, producing an implied upside calculation of 305.9%. That spread should not be read as a price forecast. It indicates that the cash-flow assumptions embedded in the model differ substantially from the risk, timing, and durability assumptions reflected in the market price.
The operating picture helps explain why the valuation debate remains unusually wide. Bristol-Myers reported first-quarter 2026 revenue of $11.5 billion, up 3%, while revenue from its Growth Portfolio increased 12% to $6.2 billion. The company also reaffirmed full-year revenue guidance of approximately $46.0 billion to $47.5 billion and adjusted earnings guidance of $6.05 to $6.35 per share, with both expected to trend toward the upper end of their ranges. At the same time, the market continues to assess patent exposure, portfolio replacement, pipeline execution, and the amount of investment required to support future growth.
For readers evaluating the DCF gap, the most useful next layer would be product-level revenue, cash-flow statements, debt data, and pipeline milestone information. Those datasets help show whether the modeled value is being supported by improving cash generation and a broader growth portfolio, or whether it depends heavily on longer-dated drug-development assumptions. Bristol-Myers' expanded use of AI in discovery may improve research productivity, but the valuation relevance will ultimately depend on measurable clinical, regulatory, and commercial outcomes.
ResMed Inc. (RMD)
DCF Value: $295.67 — Market Price: $195.27 → Upside Potential: 51.4%
ResMed's valuation gap is smaller than those of Bristol-Myers, AIG, or PayPal, but it may be easier to connect to current operating data. The FMP DCF value of $295.67 is 51.4% above the stated market price of $195.27. In this case, the signal appears less like an extreme disagreement over business viability and more like a difference in how the model and the market are pricing growth durability, margins, and the quality of earnings.
Recent financial results provide evidence for both the constructive and cautious interpretations. ResMed's fiscal second-quarter 2026 revenue rose 11% to $1.4 billion, while non-GAAP gross margin increased by 310 basis points to 62.3%. Non-GAAP operating income advanced 19%, and operating cash flow reached $340 million. Those figures show that revenue growth was accompanied by margin expansion and cash generation rather than volume growth alone. Reuters also reported that adjusted earnings exceeded consensus expectations, although analyst commentary indicated that some operating metrics still fell short of more demanding forecasts.
The next question is whether that margin profile remains stable as product mix, competitive conditions, acquisitions, and investment priorities evolve. A useful companion to the DCF endpoint would be quarterly income-statement data, segment revenue, gross-margin history, cash-flow data, and analyst estimate revisions. Those datasets would allow readers to test whether the valuation spread is supported by a sustained improvement in operating economics or is sensitive to a relatively narrow set of margin assumptions.
Accenture plc (ACN)
DCF Value: $217.82 — Market Price: $146.99 → Upside Potential: 48.2%
Accenture's FMP DCF estimate of $217.82 implies a 48.2% gap relative to the stated market price of $146.99. The difference arrives at a point when the market is reassessing the economics of consulting, outsourcing, and technology implementation in an AI-driven spending cycle. The central issue is not simply whether enterprises continue to spend on technology. It is how much of that spending flows through traditional consulting structures, how engagements are priced, and whether AI improves delivery economics or compresses billable work.
Recent industry commentary has focused on the pressure AI places on labor-based consulting models. Clients are redirecting budgets toward AI systems and demanding clearer evidence of implementation value, while consulting firms are being pushed to adopt more outcome-based commercial models. At the same time, AI adoption is creating additional work around systems integration, governance, workflow redesign, security, and organizational change. For Accenture, that produces a mixed signal: AI affects the economics of established service lines while also expanding demand for complex implementation capabilities.
The valuation gap therefore depends heavily on bookings quality, conversion of AI-related demand into revenue, utilization, pricing, and operating margin. New bookings data, segment revenue, geographic performance, headcount trends, analyst estimates, and cash-flow statements would add important context to the DCF result. In particular, comparing booking growth with realized revenue and margin performance would help determine whether the modeled cash flows are grounded in demonstrated demand or rely on an acceleration that has not yet appeared consistently in reported results.
American International Group, Inc. (AIG)
DCF Value: $355.99 — Market Price: $79.06 → Upside Potential: 350.3%
AIG produces the largest percentage disconnect in the group. Its FMP DCF value of $355.99 is 350.3% above the stated market price of $79.06. A spread of this size deserves additional scrutiny because insurance-company valuation is particularly sensitive to the treatment of capital, investment income, reserves, catastrophe exposure, and the normalization of underwriting results. A conventional cash-flow framework can produce a very different conclusion from the market when those variables are modeled aggressively or classified differently.
Recent reported performance was strong. AIG said first-quarter 2026 underwriting income more than tripled year over year to $774 million, while its calendar-year combined ratio improved by 850 basis points to 87.3%. Earlier results also showed a 48% increase in quarterly general-insurance underwriting income, supported in part by lower catastrophe losses. These figures indicate better underwriting profitability, but they also highlight the importance of distinguishing structural improvement from favorable loss activity, pricing conditions, reserve development, and reinsurance outcomes.
For AIG, the most informative supporting datasets would include combined-ratio history, catastrophe losses, prior-year reserve development, premiums written, investment income, book value, and capital-return activity. Balance-sheet and segment-level insurance data are especially important because a headline DCF spread may not fully capture the regulatory and actuarial constraints that shape distributable cash. The current result is best treated as a prompt to reconcile the model with insurer-specific fundamentals rather than as a standalone indication of mispricing.
PayPal Holdings, Inc. (PYPL)
DCF Value: $135.39 — Market Price: $56.15 → Upside Potential: 141.1%
PayPal's FMP DCF value of $135.39 sits 141.1% above the stated market price of $56.15. The gap captures a familiar tension in the company's valuation: PayPal continues to operate at substantial scale and generate meaningful cash flow, while the market applies a more restrained assessment to its growth quality, competitive position, execution record, and ability to increase the economic value of each transaction.
The latest reported figures illustrate that tension. First-quarter 2026 net revenue increased 7% to $8.4 billion, but transaction margin dollars rose at a slower 3% to $3.8 billion. GAAP operating income declined 3%, while non-GAAP operating income fell 5%. The distinction matters because transaction margin dollars offer a clearer view of the economics PayPal retains after transaction-related expenses than payment volume alone. Revenue growth without comparable margin expansion provides less support for a high DCF output, particularly when investors are also evaluating competitive pressure and product execution.
A complete reading of the signal would benefit from transaction-margin data, payment volume, branded-checkout growth, Venmo monetization, active-account trends, free cash flow, share repurchases, and analyst estimate revisions. Those endpoints would show whether the modeled value is being driven by durable improvement in unit economics, cost reductions, or assumptions about longer-term growth. The 141.1% spread identifies PayPal as a name requiring closer reconciliation between reported operating progress and the expectations embedded in the valuation model, rather than resolving that debate on its own.
Reading a Common Signal Across Unrelated Sectors
The five-company screen does not point to a single sector trade. It exposes a broader valuation pattern: modeled cash flows are assigning substantially more value to established earnings capacity than the market is currently willing to recognize. Bristol-Myers Squibb is being assessed through patent and pipeline risk, ResMed through growth durability and margin quality, Accenture through uncertainty around AI-driven changes in consulting economics, AIG through underwriting and reserve assumptions, and PayPal through transaction profitability and competitive pressure. The businesses are unrelated, but the valuation conflict is similar. In each case, the market appears to be applying a heavier discount to the reliability, timing, or transferability of future cash flows.
That distinction matters because a large DCF spread is not automatically evidence of broad mispricing. It can also reveal where a standardized model is especially sensitive to company-specific assumptions. AIG, for example, cannot be evaluated in exactly the same way as PayPal or Accenture because insurer cash flows are shaped by regulatory capital, reserves, catastrophe losses, and investment income. Bristol-Myers requires a similarly specialized reading, since product concentration, patent expirations, and clinical outcomes can materially alter the duration of projected earnings. The common signal is therefore not that all five stocks share the same opportunity. It is that each has reached a point where the market price and the model are expressing sharply different levels of confidence in future cash conversion.
A stronger workflow would treat the DCF output as an opening signal, then test its assumptions against independent financial evidence. Using standardized datasets available through FMP, revenue, operating income, and margin trends can be compared with cash generation, leverage, liquidity, and capital requirements to identify which part of the valuation case is creating the disconnect. The comparison remains consistent across companies, while the interpretation can still reflect the distinct economics of pharmaceuticals, medical devices, consulting, insurance, and payments.
Expectations data can then clarify whether the disconnect is isolated to the DCF model or visible across the wider research community. Comparing the valuation spread with FMP's Financial Estimates API can show whether revenue and EPS forecasts are rising, falling, or remaining stable. The Price Target Consensus API adds the high, low, median, and average targets, helping distinguish a broad analyst disagreement from a valuation gap driven by one modeling framework. A stock trading far below its DCF value but close to consensus estimates presents a different research question from one where both intrinsic-value models and analyst targets sit well above the market price.
The practical takeaway is that this week's screen is best understood as a map of contested assumptions. The size of each spread identifies where deeper work is warranted, but the surrounding data determines what the spread actually means. When income statements, cash flows, balance sheets, analyst estimates, price targets, and company-specific operating metrics are examined together, the screen moves beyond a ranking of theoretical upside and becomes a structured way to locate where market confidence is weakest relative to reported fundamentals.
Turning DCF Snapshots Into a Live, Repeatable Signal
A single DCF output can highlight a pricing gap, but on its own it's just a snapshot. Market prices update continuously, while model inputs—growth rates, margins, discount assumptions—shift as new data comes in. To make the signal usable, the focus needs to move from one-off checks to consistent data capture. That means running the same extraction on a schedule, storing each pull, and observing how valuation spreads change over time rather than treating them as isolated readings.
Before starting the workflow, confirm that your API key is properly configured and accessible in your environment.
Step 1. Query the DCF Valuation API
The workflow starts with the DCF Valuation API, which serves as the foundation for the entire process. This endpoint returns both the modeled intrinsic value and the current market price in one response, removing the need to reconcile multiple data sources before analysis begins. Having valuation and price captured together ensures consistency and reduces the risk of timing mismatches that can distort comparisons.
Sample response
|
[ { "symbol": "AAPL", "date": "2025-02-04", "dcf": 147.27, "Stock Price": 231.80 } ] |
Step 2. Compute the Upside
With both fields in hand, the next step is to normalize the gap. Converting the difference between DCF and market price into a percentage allows the results to be compared across names with very different share prices:
Upside % = (DCF - Stock Price) / Stock Price × 100
In the example above, the calculation produces roughly -36%, indicating the stock is trading above the modeled intrinsic value. Positive figures flag the opposite condition—where price sits below DCF—which is the core signal this screen is designed to capture.
Step 3. Scale It into a Screening Loop
The workflow becomes materially more useful once this logic is applied at scale. Running the DCF endpoint across a defined universe, calculating the percentage spread for each symbol, storing the results, and ranking them by upside converts a static check into a living screen. When automated on a recurring cadence, the process continuously surfaces where price and intrinsic value are drifting further apart or beginning to converge, making it easier to monitor valuation pressure as market conditions shift.
Stabilizing the Workflow Before Scaling It
Before expanding a valuation screen across hundreds or thousands of symbols, the more important question is whether the process behaves consistently under repeat conditions. Early-stage testing is less about market coverage and more about validation: confirming that DCF outputs reconcile properly, percentage spreads calculate cleanly, and rankings update logically as new data enters the system. For that stage, the FMP Basic plan is generally enough to establish whether the workflow itself is dependable.
Once the mechanics are stable, scaling becomes an infrastructure decision rather than a methodological one. The same extraction logic, normalization process, and ranking framework can simply be applied across a broader universe using the FMP Starter plan, which adds wider market coverage and deeper historical access. The signal itself does not change — only the breadth of the environment it runs against. That consistency matters because it keeps comparisons aligned as the dataset expands.
For workflows operating on tighter refresh cycles or across international markets, throughput starts to matter more than screen construction. The FMP Premium plan supports that transition with higher request capacity and broader exchange access, making it easier to run the process continuously around earnings releases, estimate revisions, or macro-driven volatility windows. At that stage, the screen stops functioning like a periodic valuation check and starts behaving more like part of the ongoing research infrastructure.
When a Valuation Framework Evolves into Research Infrastructure
Signals that consistently hold up under market pressure rarely remain confined to a single analyst workflow. Once a valuation framework starts influencing sector reviews, allocation discussions, or risk meetings, the limitations of fragmented implementations become more visible. Teams may be using the same conceptual model, but differences in ticker universes, update frequency, normalization logic, or historical storage quickly create inconsistencies that undermine comparability across desks.
In practice, the analysts closest to the workflow often become the internal drivers of standardization. After refining the screen through repeated market cycles, the priority shifts away from experimentation and toward consistency: locking calculation logic, aligning data inputs, and ensuring that everyone evaluating the signal is working from the same underlying assumptions. That transition matters because valuation frameworks become materially more useful once they can be referenced across teams without requiring reconciliation between separate spreadsheets or independently maintained scripts.
As adoption expands across research groups, portfolio teams, or regional desks, the infrastructure surrounding the workflow becomes as important as the screen itself. Shared dashboards reduce duplication, centralized storage preserves historical outputs for auditability, and permission controls help prevent silent methodology drift over time. The objective is not simply operational efficiency — it is analytical coherence. When multiple teams are discussing valuation dispersion, factor exposure, or earnings sensitivity, confidence in the conversation depends on confidence in the underlying data framework being synchronized across the organization.
That is typically the point where desk-level tooling evolves into institutional research infrastructure. Frameworks that began as analyst-built screens often migrate toward more formal environments designed for controlled access, consistent delivery, and governance across broader user groups. An institutional setup such as the FMP Enterprise Plan becomes relevant less as a scaling upgrade and more as a way to preserve methodological integrity as usage broadens across teams, strategies, and regions.
Putting This Week's Valuation Signals into Broader Context
The five gaps identified by the FMP DCF Valuation API are best viewed as starting points for further research, not conclusions in isolation. The next step is to track whether reported fundamentals and market expectations begin to narrow these disconnects or provide clearer justification for them.
Expand your watchlist with our previous deep dive: Weekly Signals Desk | Price-Target Gaps Identified via the FMP API (July 13-17)
Disclosure: Signals Desk content is provided for informational and analytical purposes only and does not constitute investment advice or trade recommendations. The analysis reflects interpretation of market data and publicly disclosed or third-party information, including data accessed via Financial Modeling Prep APIs, at the time of publication. Signals discussed are probabilistic, can be wrong, and may change as market conditions and consensus data evolve. This content should be considered alongside broader research, individual objectives, and risk assessment.
